Erythromycin nalidixate was prepared by combining nalidixic acid with
erythromycin base. Thin-layer chromatographic studies and infrared abs
orption spectrum confirmed homogeneity of the new salt. The salt is ve
ry soluble in nonpolar solvent and freely soluble in polar solvent. Th
e salt is quite stable at room temperature (30 +/- 1 degrees C). The a
ntimicrobially active dose of the salt was found to be 820 mu g/mg. Se
rum protein binding amounted to 85% and was reversible LD(50) in mice
was found to be 371.5 mg/kg when the intraperitoneal route was used.